Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS)
Centro singular
![Foto de Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS)](/img/noimage.png)
![Foto de University of Eastern Finland](/img/noimage_org.png)
University of Eastern Finland
Kuopio, FinlandiaPublicacións en colaboración con investigadores/as de University of Eastern Finland (30)
2024
-
Discovery and in vitro Evaluation of Novel Serotonin 5-HT2A Receptor Ligands Identified Through Virtual Screening
ChemMedChem, Vol. 19, Núm. 14
2023
-
Development and Characterization of Novel Selective, Non-Basic Dopamine D2 Receptor Antagonists for the Treatment of Schizophrenia
Molecules, Vol. 28, Núm. 10
-
Discovery of novel arylpiperazine-based DA/5-HT modulators as potential antipsychotic agents – Design, synthesis, structural studies and pharmacological profiling
European Journal of Medicinal Chemistry, Vol. 252
-
Erratum: Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (Nature communications (2021) 12 1 (3417))
Nature communications
-
Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds-synthesis, biological activity, and structural evaluation
Journal of enzyme inhibition and medicinal chemistry, Vol. 38, Núm. 1, pp. 2209828
2022
-
Activity and Expression of Carboxylesterases and Arylacetamide Deacetylase in Human Ocular Tissues
Drug metabolism and disposition: the biological fate of chemicals, Vol. 50, Núm. 12, pp. 1483-1492
-
Allosteric modulation of dopamine D2L receptor in complex with Gi1 and Gi2 proteins: the effect of subtle structural and stereochemical ligand modifications
Pharmacological Reports, Vol. 74, Núm. 2, pp. 406-424
-
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Acta Neuropathologica, Vol. 144, Núm. 5, pp. 821-842
-
In vitro and in vivo evaluation of antioxidant and neuroprotective properties of antipsychotic D2AAK1
Neurochemical Research, Vol. 47, Núm. 6, pp. 1778-1789
-
Multitarget Derivatives of D2AAK1 as Potential Antipsychotics: The Effect of Substitution in the Indole Moiety
ChemMedChem, Vol. 17, Núm. 15
-
New insights into the genetic etiology of Alzheimer's disease and related dementias
Nature genetics, Vol. 54, Núm. 4, pp. 412-436
2021
-
Breast cancer risk genes - Association analysis in more than 113,000 women
New England Journal of Medicine, Vol. 384, Núm. 5, pp. 428-439
-
Common variants in Alzheimer's disease and risk stratification by polygenic risk scores
Nature communications, Vol. 12, Núm. 1, pp. 3417
-
N-(3-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}propyl)-1H-indazole-3-carboxamide (D2AAK3) as a potential antipsychotic: In vitro, in silico and in vivo evaluation of a multi-target ligand
Neurochemistry International, Vol. 146
-
Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity
Cancer Research, Vol. 81, Núm. 19, pp. 4901-4909
2020
-
N-(2-hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl]piperidine-4-carboxamide (d2aak4), a multi-target ligand of aminergic gpcrs, as a potential antipsychotic
Biomolecules, Vol. 10, Núm. 2
-
PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 154, pp. 330-337
2019
-
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2)
Nature Genetics
-
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing
Nature Genetics, Vol. 51, Núm. 3, pp. 414-430
-
Genome-wide association study of germline variants and breast cancer-specific mortality
British Journal of Cancer, Vol. 120, Núm. 6, pp. 647-657